Brief: Medivir: Promising Interim Data, First Complete Response In Phase 1b/2a HCC Study With Fostrox In Combination With Lenvima
04/09/2023 07:36
Sept 4 (Reuters) - Medivir AB MEDIVIR.ST :
* MEDIVIR REPORTS PROMISING INTERIM DATA, INCLUDING A FIRST
COMPLETE RESPONSE IN PHASE 1B/2A HCC STUDY WITH FOSTROX IN
COMBINATION WITH LENVIMA
* INTERIM DATA FROM PHASE 1B FURTHER STRENGTHENS PREVIOUSLY
REPORTED PROMISING SAFETY AND EFFICACY DATA
Source text for Eikon: ID:nWkr4qZk1J
Further company coverage: MEDIVIR.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))